var path='https://www.tickertech.net'; function heading(heading) { document.write('
'+heading+' |
'+ ''+ ' |
'); } function hiLite(imgDocID,imgObjName) { document.images[imgDocID].src = eval(imgObjName + ".src"); } function showStatus(toshow) { window.status = toshow; } function checkChoose() { if (document.choose.ticker.value == "") { alert("Please enter symbols before clicking the go button"); return false; } else return true; } function popJT(url,name){ var xwid = screen.width; xwid = xwid - 10; javaticker = window.open(url,name,'width='+xwid+',height=100,resizable=yes,scrollbars=no,toolbar=no,location=no,directories=no,status=yes,menubar=no'); javaticker.opener.name="opener"; //javaticker.moveTo(0,30); } var allow = 0; var ref = ""+location; if ((ref.indexOf("cryptocurrencieschannel.com") > 0) || (ref.indexOf("cefchannel.com") > 0) || (ref.indexOf("bdcinvestor.com") > 0) || (ref.indexOf("tickertech.com") > 0) || (ref.indexOf("xxxx:") > 0) || (ref.indexOf("javascript:") > 0) || (ref.indexOf("filseclab.com") > 0) || (ref.indexOf("msnscache.com") > 0) || (ref.indexOf("toolbar.google.com") > 0) || (ref.indexOf("etfchannel.com") > 0) || (ref.indexOf("marketnewsvideo.com") > 0) || (ref.indexOf("news.google.com") > 0) || (ref.indexOf("dividendchannel.com") > 0) || (ref.indexOf("www.google.com") > 0) || (ref.indexOf("energystockchannel.com") > 0) || (ref.indexOf("metalschannel.com") > 0) || (ref.indexOf("portfoliochannel.com") > 0) || (ref.indexOf("canadastockchannel.com") > 0) || (ref.indexOf("theonlineinvestor.com") > 0) || (ref.indexOf("investhelp.com") > 0) || (ref.indexOf("preferredstockchannel.com") > 0) || (ref.indexOf("stockoptionschannel.com") > 0) || (ref.indexOf("holdingschannel.com") > 0) || (ref.indexOf("tickertech.net") > 0) || (ref.indexOf("historicalstockprice.com") > 0) || (ref.indexOf("splithistory.com") > 0) || (ref.indexOf("stocksplithistory.com") > 0) || (ref.indexOf("google.c") > 0) || (ref.indexOf("208.71.46.190") > 0) || (ref.indexOf("search.yahoo") > 0) || (ref.indexOf("sharesoutstandinghistory.com") > 0) || (ref.indexOf("marketcaphistory.com") > 0) || (ref.indexOf("ytdreturn.com") > 0) || (ref.indexOf("averageannualreturn.com") > 0) || (ref.indexOf("redinews.com") > 0) || (ref.indexOf("technicalanalysischannel.com") > 0) || (ref.indexOf("stockdma.com") > 0) || (ref.indexOf("stockrsi.com") > 0) || (ref.indexOf("stockmacd.com") > 0) || (ref.indexOf("topdividends.com") > 0) || (ref.indexOf("monthlydividendpayingstocks.com") > 0) || (ref.indexOf("nextearningsdate.com") > 0) || (ref.indexOf("pastearnings.com") > 0) || (ref.indexOf("historicalperatio.com") > 0) || (ref.indexOf("historicalearnings.com") > 0) || (ref.indexOf("webcache.googleusercontent.com") > 0)) { allow = 1; } function ShowTTIPage() { if (allow) { document.write('\n'); } if (allow) { document.write('
\n'); } if (allow) { document.write('4/25 - 10:57 AM \; \; | \n'); } if (allow) { document.write('Dow Movers: IBM, MRK [VIDEO] | \n'); } if (allow) { document.write('
4/25 - 6:30 AM \; \; | \n'); } if (allow) { document.write('Merck Announces First-Quarter 2024 Financial Results | \n'); } if (allow) { document.write('
4/19 - 7:06 AM \; \; | \n'); } if (allow) { document.write('Health Canada Approves KEYTRUDA®\; as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy | \n'); } if (allow) { document.write('
4/19 - 7:05 AM \; \; | \n'); } if (allow) { document.write('Health Canada Approves KEYTRUDA as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy | \n'); } if (allow) { document.write('
4/4 - 6:45 AM \; \; | \n'); } if (allow) { document.write('Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer | \n'); } if (allow) { document.write('
4/3 - 8:00 AM \; \; | \n'); } if (allow) { document.write('REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer | \n'); } if (allow) { document.write('
4/1 - 6:45 AM \; \; | \n'); } if (allow) { document.write('Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25 | \n'); } if (allow) { document.write('
3/28 - 9:16 AM \; \; | \n'); } if (allow) { document.write('How We Can Strengthen Vaccination Programs and Build Vaccine Confidence Together | \n'); } if (allow) { document.write('
3/28 - 6:45 AM \; \; | \n'); } if (allow) { document.write('European Commission Approves Merck\'s KEYTRUDA (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults | \n'); } if (allow) { document.write('
3/27 - 10:20 AM \; \; | \n'); } if (allow) { document.write('S&P 500 Movers: CCL, CTAS [VIDEO] | \n'); } if (allow) { document.write('
3/27 - 10:19 AM \; \; | \n'); } if (allow) { document.write('Dow Movers: V, MRK [VIDEO] | \n'); } if (allow) { document.write('
3/26 - 6:21 PM \; \; | \n'); } if (allow) { document.write('FDA Approves Merck\'s WINREVAIR™\; (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO Group 1) | \n'); } if (allow) { document.write('
3/26 - 9:31 AM \; \; | \n'); } if (allow) { document.write('Merck Foundation Strengthens Its Commitment to Expanding Access to Care in Asia-Pacific Region | \n'); } if (allow) { document.write('
3/21 - 6:45 AM \; \; | \n'); } if (allow) { document.write('Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA (pembrolizumab) Plus Maintenance LYNPARZA (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer | \n'); } if (allow) { document.write('
3/20 - 10:13 AM \; \; | \n'); } if (allow) { document.write('Dow Movers: CAT, CSCO [VIDEO] | \n'); } if (allow) { document.write('
3/19 - 9:00 AM \; \; | \n'); } if (allow) { document.write('Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults | \n'); } if (allow) { document.write('
3/15 - 4:25 PM \; \; | \n'); } if (allow) { document.write('FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform | \n'); } if (allow) { document.write('
3/15 - 6:45 AM \; \; | \n'); } if (allow) { document.write('Merck\'s KEYTRUDA (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer | \n'); } if (allow) { document.write('
3/13 - 3:00 AM \; \; | \n'); } if (allow) { document.write('Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL9 | \n'); } if (allow) { document.write('
3/11 - 8:15 AM \; \; | \n'); } if (allow) { document.write('Merck Completes Acquisition of Harpoon Therapeutics, Inc. | \n'); } if (allow) { document.write('
more news | \n'); } if (allow) { document.write('\n'); } if (allow) { document.write(' |